Sort
23,748 grants matching “melanoma”
DISSECTING THE ROLES OF ARID2 TUMOR SUPPRESSOR IN METASTATIC MELANOMA
$665,999Yale Univ · · FY2016 · Department of Defense
Social Health, Activity Behaviors, and Quality of Life among Young Adult Cancer Survivors: A Longitudinal Study
$665,769Kimberly Ann Miller · University Of Southern California · R37 · FY2022 · CA
An innovative, curriculum-based integrated sun exposure behavior intervention for
$665,619Myles G Cockburn · University Of Southern California · R01 · FY2014 · CA
Mechanisms driving acute and chronic kidney function decline after immune checkpoint inhibitor therapy for cancer
$665,456Meghan E. Sise · Massachusetts General Hospital · R01 · FY2025 · DK
Determinants of toxicity and response to immune checkpoint blockade through integrative profiling of T cell clonal dynamics and plasma cell- free DNA
$665,413Aadel Chaudhuri · Mayo Clinic Rochester · R01 · FY2025 · CA
A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-601) Administered to Patients with Relapsed Non-Hodgkin Lymphoma
$665,000Juan Fernando Vera · Marker Therapeutics, Inc. · R44 · FY2025 · CA
A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-601) Administered to Patients with Relapsed Non-Hodgkin Lymphoma
$665,000Juan Fernando Vera · Marker Therapeutics, Inc. · R44 · FY2024 · CA
Determinants of Melanocyte Transformation and Melanoma Progression
$664,834Thomas J Hornyak · Basic Sciences · Z01 · FY2007 · CA
Spatial genomic tools to interrogate T cell clonotypes, tumor clones and the microenvironment
$664,636Fei Chen · Broad Institute, Inc. · R01 · FY2024 · CA
Optimizing Detection and Interventions Against Rare Pre-existing Drug Resistance Mutations
$664,591Lawrence Kwong · University Of Tx Md Anderson Can Ctr · R01 · FY2021 · HG
Optimizing Detection and Interventions Against Rare Pre-existing Drug Resistance Mutations
$664,591Lawrence Kwong · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · HG
Optimizing Detection and Interventions Against Rare Pre-existing Drug Resistance Mutations
$664,591Lawrence Kwong · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · HG
Genomic-wide Kinase Sequencing of Pediatric Brain Tumors
$664,478Dana-Farber Cancer Institute · R01 · FY2004 · CA
Tumor infiltrating lymphocyte therapy for human papillomavirus-positive cancers
$664,454Christian Hinrichs · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
CCR Confocal Microscopy Core
$664,432Susan Garfield · Division Of Basic Sciences - Nci · ZIC · FY2011 · CA
A digital intervention to improve skin self-examination among melanoma survivors
$664,230Sharon L Manne · Rbhs -Cancer Institute Of New Jersey · R01 · FY2022 · CA
Mechanisms of non-classical multidrug resistance in cancer
$664,041Michael Gottesman · Basic Sciences · Z01 · FY2007 · CA
Role of HSP90 Family Chaperone Proteins in Cellular Signal Transduction
$663,995Leonard Neckers · Division Of Clinical Sciences - Nci · Z01 · FY2008 · CA
Project 3: Tools for Capturing Immune Cell/Cancer Cell Interactions in Cancer Immunotherapies and Combination Immunotherapies
$663,909James R. Heath · Institute For Systems Biology · U54 · FY2018 · CA
Novel Paxillin-FAK Inhibitors for the Treatment of Liver Fibrosis
$663,777Timothy A Marlowe · Faknostics, Llc · R42 · FY2025 · DK
Therapeutic targeting of RNA splicing catalysis through inhibition of Protein Arginine Methylation
$663,748Ernesto Guccione · Icahn School Of Medicine At Mount Sinai · R01 · FY2021 · CA
ER stress-driven IRE1a-XBP1 signaling in lung cancer
$663,481Vivek Mittal · Weill Medical Coll Of Cornell Univ · R01 · FY2025 · CA
ER stress-driven IRE1a-XBP1 signaling in lung cancer
$663,481Vivek Mittal · Weill Medical Coll Of Cornell Univ · R01 · FY2023 · CA
EARLY DETERMINANTS OF MELANOMA METASTASIS
$663,465New York University · · FY2021 · Department of the Army
PROCESSED ANTIGEN CHARACTERIZATION BY MASS SPECTROMETRY
$663,194Donald F Hunt · University Of Virginia · R37 · FY2007 · AI